New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 16, 2013
07:05 EDTDGXQuest Diagnostics plans to sell HemoCue diagnostic products business
Quest Diagnostics announced that it plans to sell its HemoCue diagnostic products business, as part of the company's strategy to refocus on diagnostic information services. HemoCue develops, produces and markets point-of-care testing systems. As a result, Quest Diagnostics will report 2012 and 2011 results for HemoCue and its OralDNA products business, which was sold in December, 2012, as discontinued operations in its report of fourth quarter 2012 results, and take related after-tax charges in discontinued operations for the estimated asset impairment associated with HemoCue and the loss on sale associated with OralDNA, totaling $89.5M, or 56c per diluted share, in the period. The company's consolidated income statements for FY12 and 2011 will present the operating results of HemoCue and OralDNA as discontinued operations. As such, results from continuing operations will be reduced as follows: Revenues by $117M in 2012 and $119M in 2011; Operating income by $11M in 2012 and $8M in 2011; Net income from continuing operations by $15M in 2012 and $13M in 2011; and EPS by 9c in 2012 and 8c in 2011.
News For DGX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 23, 2015
07:08 EDTDGXQuest Diagnostics backs FY15 adjusted EPS view $4.70-$4.85, consensus $4.78
Subscribe for More Information
07:06 EDTDGXQuest Diagnostics reports Q1 adjusted EPS $1.05, consensus $1.04
Subscribe for More Information
April 22, 2015
15:50 EDTDGXNotable companies reporting before tomorrow's open
Subscribe for More Information
April 21, 2015
08:14 EDTDGXQuest Diagnostics and Inserm launch BRCA Share initiative
Quest Diagnostics (DGX) and Inserm, the French National Institute of Health and Medical Research institution, launched BRCA Share, a novel datashare initiative they co-founded to provide scientists and laboratory organizations around the world with open access to BRCA1 and BRCA2 genetic data. The program's goal is to accelerate research on BRCA gene mutations, particularly variants of uncertain significance, to improve the ability of clinical laboratory diagnostics to predict which individuals are at risk of developing hereditary breast and ovarian cancers. Laboratory Corporation of America Holdings (LH) is the first participant in the initiative, which is structured as a user group. B
06:40 EDTDGXStart-up to offer saliva test for breast cancer susceptibility, NY Times says
Subscribe for More Information
April 15, 2015
12:32 EDTDGXFocus Diagnostics announced FDA clearance for Simplexa Group A Strep Direct Kit
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use